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This work covers new findings on hypertrophic cardiomyopathy. The definition, genetic
findings, genotype-phenotype relationships, incidence, and prognosis of the disease are
reviewed. The latest recommendations for treatment are discussed, particularly percuta-
neous transluminal septal myocardial ablation and septal myectomy in severely sympto-
matic obstructive forms.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Hypertrophic cardiomyopathy (HCM) is a disease character-
ized by hypertrophy of the interventricular septum and/or
left ventricle, diastolic dysfunction, and in some patients also
by systolic obstruction in the left and rarely right outflow
tract [1,2]. The disease was described for the first time in 1957
by Brock (quotation from 1). The detailed pathological-
anatomical description was published by Teare next year
(quotation from 1). He likened the marked myocardial hyper-
trophy to a tumor of the heart.
The view on HCM has changed many times since that time.
The aim of our work is to summarize knowledge, which has
changed our view on various aspects of HCM in last years.2. What is considered HCM?
The publication of the new classification of European Society of
Cardiology that significantly changed definition of HCM meant
the first substantial change [3]. According to the new classifica-
tion, cardiomyopathies are disorders in which cardiac muscle is
structurally and functionally abnormal in the absence of
another cardiac disease, including CAD, hypertension, valve
disease, or congenital heart disease that would cause myocar-
dial abnormality. It means that while only idiopathic forms
were considered HCM until recently, now also other conditions
that may cause hypertrophy are ranked among HCMs, for
example lysosomal storage disorders (Fabry’s disease), glycogen
storage diseases (Pompe’s disease, Danon’s disease), myocardial
hypertrophy in Friedreich’s ataxia, or initial stages of amyloi-
dosis, Noonan’s syndrome, mitochondrial diseases, carnitine
deficiency, or hypertrophy in infants of diabetic mothers, etc. In
our text, we will focus on ‘‘classic’’ so called idiopathic forms of
HCM since covering the whole spectrum of cardiomyopathies is
beyond the scope of this paper.3. Etiology of HCM—genetics
Since the beginning, HCM unlike dilated cardiomyopathies was
known to be a genetic disorder. It was assumed that detailedTable 1 – Genes responsible for HCM.
Protein and gene abbreviation Locus
Beta-myosin heavy chain (MYH7) 14q12
Myosin binding protein C (MYPBC3) 11p11.2
Troponin T (TNNT2) 1q32
Troponin I (TNNI3) 19p13.4
Alpha-tropomyosin (TPM1) 15q22.1
Cardiac myosin light chain, regulatory (MYL2) 12q24.3
Cardiac myosin light chain, essential (MYL3) 3p21
Aktin (ACTC) 15q14
Titin (TTN) 2q31
Cardiac LIM protein (CSRP3) 11p15.1
Telethonin (TCAP) 2q24.3
Myozenin 2 (MYOZ2) 7q36
Vinculin (VCL) 14q11.2genetic testing in this disease will bring important findings. HCM
is also the first cardiologic disorder studied at themolecular level
and is used as a model for genetic studies. Mutations of genes
encoding the cardiac sarcomere are responsible for pathogenesis
of this disease. The first important information on this topic was
published in 1989 when Jarcho et al. proved association between
HCM and a locus mapped to the long arm of chromosome 14 [4].
They presumed that the candidate gene responsible for HCM
was one of the genes for beta-myosin or heat shock protein. Its
precise identification was not long awaited. One year later,
Salomon et al. discovered that the gene for beta-myosin is
responsible for familiar HCM [5]. This finding raised big expecta-
tions because the identification of the candidate gene could have
led to precise mapping of responsible mutation by PCR or direct
sequencing. Thereafter nothing would be in the way of applica-
tion of genetic methods in direct diagnostics, genetic counseling,
and eventually also in prenatal diagnostics [6].
The situation became complicated when it had proved that at
least in two families with HCM, the gene responsible for the
disease had not been located on the chromosome 14 [5]. The
hypothesis was proposed that HCM could have been caused by
mutations in two different genes that encoded different pro-
teins with similar function. Since we know that the beta-
myosin is a protein of the muscle sarcomere, further attention
was concentrated on its other components. Other genes (or
rather their products—proteins) responsible for HCM have also
been identified one by one. They are listed in Table 1.
At present, more than 1000 mutations in above mentioned
genes are known. However, none of the mutations is pre-
dominant [7]. The most mutations have been found in the
gene for the beta-myosin heavy chain and myosin binding
protein C. Surprisingly in the Czech population, mutations in
the gene for the myosin binding protein C are more common
than for beta-myosin heavy chain. New unknown mutations
are still being discovered [8,9]. The mutation distribution
along genes is uneven. There are regions with their frequent
occurrence and, on the contrary, regions where no mutation
has been found [10].
The former concept that the certain genotype is associated
with the specific form of HCM with particular morphological
and functional features and prognosis has not been con-
firmed [8]. For example, it was reported in the past that the
mutation in the cardiac troponin T gene was associated withComponent of the sarcomere Frequency (%)
Thick filaments 44
Thick filaments 35
Thin filaments 7
Thin filaments 5
Thin filaments 2.5
Thick filaments 2
Thick filaments 1
Thin filaments 1
Thick filaments o1
Z-disc o1
Z-disc o1
Z-disc o1
Intercalated disc o1
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 0 0 – e 3 0 4e302mild (or even none) hypertrophy but serious prognosis of
sudden death [11], however, it has been found later that this
risk might be, on the contrary, very low [12].4. Is HCM a rare disease?
The answer to this question has changed significantly in last
years. Epidemiological studies in various populations have
shown consistent prevalence rates of phenotypic features of
HCM in adult population of approximately 0.2% (1 out of 500
adults) [13,14]. Low occurrence of this condition among com-
mon cardiological patients – around 1% of patients referred for
an echocardiographic examination [13] – can be explained by
the fact that majority of the patients are asymptomatic and
that is why they escape diagnosis. The prevalence rate of HCM
ranges from 0.02 to 0.2%. Nowadays, rather the upper limit of
this range 0.2% is widely accepted. It accounts for about 20,000
patients in Czech Republic [2], and we still discuss only so-
called idiopathic forms and do not include conditions falling
under the extended definition of cardiomyopathies by ESC.
Therefore we do not refer to HCM as a rare disease, but as the
most common monogenic genetic disorder.
The primary screening method is ECG, which is pathologi-
cal in 75% to 95% of patients. The ECG changes may precede
development of hypertrophy and/or clinical symptoms [15].
The gold standard for the diagnosis of HCM is echocardio-
graphy. An echocardiogram shows idiopathic left ventricular
hypertrophy (in most cases more than 15 mm in men and
13 mm in women) [16].5. Obstruction
We do not deal with obstruction in details in this paper, two
newer findings should be, however, mentioned in this con-
text. Mitral valve leaflets elongation have been proven in
HCM. This morphological abnormality is responsible for left
ventricular obstruction in combination with small outflow
tract dimension [17].
Isosorbide dinitrate appeares reliable provoking test for
detection of HCM obstruction with good sensitivity and
specificity [18]. Measurement should be delayed 5–10 min
after application of ISDN.6. What is prognosis of HCM?
Until recently, it was generally accepted that HCM was a
disease with utterly unfavorable prognosis. It was believed
that those affected were anytime in danger of sudden death,
which struck more likely majority of them. The mortality rate
was estimated at 2% to 4% in adults and 6% in children. The
majority of deaths were sudden [19,20].
Current opinions on this issue are completely different.
HCM is a relatively benign disease with the annual mortality
rate falling below 1% in last 40 years. Approximately one half
of deaths are sudden and the rest of them are caused by heart
failure and stroke [21,22]. The situation has not changed as a
consequence of better treatment (with an exception of ICDimplantation in last years), but rather due to more sensitive
diagnostic procedures. We are able to recognize milder forms
of the disease, which was not possible to identify before.
Particularly asymptomatic and oligosymptomatic patients
have a favorable prognosis, while patients with severe left
ventricular outflow tract obstruction (Vmax44 m/s) have
worse prospects, and course of the disease is more frequently
complicated by heart failure in those patients [23].
However, it would be wrong to be excessively optimistic.
HCM still takes its toll in deaths, especially of young people.
For example, in children 6 to 18 years of age, HCM is the main
cause of sudden death, together with arrhythmogenic right
ventricular dysplasia [24].7. How to treat HCM?
Most of the symptoms in non-obstructive forms of HCM are
caused by diastolic dysfunction [25]. Since treatment of
diastolic dysfunction is problematic, also treatment of non-
obstructive HCM is difficult. Beta-blockers or calcium channel
blockers (verapamil, diltiazem) are commonly used.
Also therapy with ACE inhibitors has some therapeutic
potential, as we already demonstrated 15 years ago [26]. Since
we were not able to arrange a double-blind, placebo-controlled
trial at that time for financial reasons, our results had only
limited validity. Further data confirmed later that it was useful
to study drugs acting on renin–angiotensin–aldosterone system
in patients with HCM [27]. Later we managed to organize a
double-blind, placebo-controlled trial with candesartan and its
results were very encouraging [28–30].
A very important treatment modality is ICD implantation.
ICD should be implanted in patients with HCM who have at
least one of five known risk factors of sudden cardiac death
(family history of sudden cardiac death, syncope, LV wall
thickness more than 30 mm, abnormal exercise blood pres-
sure, nonsustained ventricular tachycardia), or personal his-
tory of spontaneous sustained ventricular tachycardia, or
cardiac arrest [31]. CMR late gadolinium enhancement
defined fibrosis had been linked to the substrate for VT/VF
and it may probable serve as a predictor of thise arrhythmias
in HCM patients [32]. As far as ICD implantation is concern,
there may be a higher risk for device complications and
inappropriate shocks in HCM, especially of younger patients
and those with atrial fibrillation [33].
There are several other options of treatment for patients
with obstructive HCM. Disopyramide – a type I antiarrhyth-
mic drug with negative inotropic action – can be adminis-
tered. However, this drug is not used in Czech Republic. We
can also recommend beta-blockers and calcium channel
blockers in this indication. Though calcium channel blockers
might be associated with obstruction worsening (probably
due to vasodilatation) and increased incidence of sudden
death in patients with severe obstruction [19,25].
Dual chamber pacing has been used historically in patients
with obstructive HCM. This treatment option has proven to
be less effective than expected and it acts as placebo in many
cases [34]. Nowadays, dual chamber pacing is recommended
in those symptomatic patients in whom myectomy or
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(PTSMA) cannot be performed [35].8. Is better PTSMA or surgical myectomy?
Both methods play an essential role in symptomatic patients
with obstructive form. It has been repeatedly discussed recently
which of the above mentioned methods is better and more
beneficial for patients. Unfortunately, no randomized trial has
been performed that would resolve this question and according
to some authors, it is not feasible to design such trial [36].
Therefore it is not possible to get a conclusive answer, but we
still can try to answer this question. Cardiac surgery – trans-
aortic septal myectomy – was introduced already almost half a
century ago by Morrow (also called Morrow procedure). Septal
myectomy still remains gold-standard therapy in the USA. The
surgery has now low mortality (below 0.5% in experienced
centers) and might be associated with lower incidence of
sudden cardiac death in comparison to remaining HCM popu-
lation [37–39]. Mitral regurgitation improves in most cases after
procedure or it can be specifically treated during surgery in
severe cases (for example mitral valve repair can be performed
if prolapse is present).
During PTSMA, concentrated alcohol is injected into the first
and in some case also second septal branch of the left anterior
descending artery. Shorter hospital stay and absence of ster-
notomy are advantages of PTSMA. A drawback of this proce-
dure may be necessity of pacemaker placement in some
patients (20–25% formerly, now in experienced centers around
10%) [37,40]. Procedural success is achieved in 70–75% of cases.
The resultant myocardial infarctions after PTSMA are small,
but they still could create new arrhythmogenic substrates.
Nevertheless higher incidence of arrhythmogenic complica-
tions has not been proved so far. The mortality rate of this
procedure is now 1–2% [41,42]. Lately, PTSMA is predominant
in Europe, even in countries as Germany where transaortic
septal myectomies were more common in the past.
Symptomatic improvements are comparable after both proce-
dures. However, improvement after myectomy appears to be
more durable and slightly more prominent, even in exercise
parameters [43,44]. Also further prospect of patients is probably
better after the surgical procedure [33,40]. American guidelines
recommend choosing surgical myectomy in symptomatic, parti-
cularly younger individuals, while PTSMA mostly in those cases
where operation is contraindicated, particularly in older patients
[45]. Meta-analyses comparing both methods do not show
consistent results. Two publications have not reported differ-
ences in incidence of sudden cardiac death and overall mortality
[43,46]. Results of other works however have suggested bigger
benefit after septal myectomy, both in lower mortality rates
(early and late mortality) and symptomatic improvement of
patients [42,47,48]. On top of that, the effect of the operation
appears to be more stable [49]. Also other factors play an
important role and they can influence outcome of PTSMA—for
example the amount of injected ethanol [40,50], and generally
also presence and nature of comorbidities [51]. Experience of the
center with the particular method is important too. This experi-
ence is given mostly by number of performed procedures, which
can create a limitation in Czech Republic.Acknowledgments
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